Strides acquires identified ANDAs from Nostrum Laboratories, Inc., USA
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science Limited has acquired a set of identified ANDAs (Abbreviated New Drug Applications, i.e., approved generic drug filings) from Nostrum Laboratories, Inc., based in the USA. The acquisition adds approved generic products to Strides' existing US portfolio, expanding its presence in the US generics market. Specific financial terms, product count, and deal value were not disclosed in the headline. The deal aligns with Strides' ongoing strategy of growing its regulated market business through selective product and portfolio acquisitions.
This is a portfolio-broadening acquisition that strengthens Strides' US generics pipeline, likely viewed as a positive growth signal by investors. Since financial terms and product details are not yet visible, the stock reaction may be muted until further disclosures on deal value and revenue potential are made.